{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T19:40:18Z","timestamp":1765654818142,"version":"3.48.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007065","name":"Universit\u00e0 degli Studi di Salerno","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rituximab and obinutuzumab, anti-CD20 monoclonal antibodies, are widely employed for treatment of follicular lymphoma (FL) by targeting both neoplastic and normal CD20-expressing B lymphocytes, consequently inducing immunosuppression. In this condition, viral reactivations are common and represent a major cause of morbidity and mortality. In this single-center two-arm observational real-life study, we evaluated incidence, immunological and serological status, and clinical outcomes of cytomegalovirus (CMV) reactivation in FL patients treated with bendamustine\u2009+\u2009rituximab (R-BENDA;\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200923) or obinutuzumab (G-BENDA;\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200923). CMV reactivation more frequently occurred in patients treated with R-BENDA compared to G-BENDA (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.022), and immune kinetics showed significant differences between the two groups, with a deeper and earlier immunosuppression in R-BENDA treated subjects. Moreover, R-BENDA group displayed a significant higher risk of CMV reactivation compared to G-BENDA (hazard ratio, 2.232; 95% confidence interval 1.107\u20134.500;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0249). However, G-BENDA patients tended to have a shorter 5-year overall survival (59% vs. 86.7%, G-BENDA vs. R-BENDA;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0903). By multivariate analysis, B symptoms were an independent predictor of CMV reactivation, and high baseline SUV as an additional risk factor in R-BENDA patients. In conclusion, anti-CD20 agent could increase the risk of CMV reactivation in FL patients, especially in R-BENDA treated subjects who experienced early and deep immunosuppression. Therefore, close monitoring of clinical and laboratory data may improve outcomes in FL patients by preventing CMV disease, especially in those treated with rituximab who are more prone to viral reactivation. However, larger prospective studies are required to confirm our preliminary results.\n                  <\/jats:p>","DOI":"10.1007\/s00432-025-06351-2","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:18:18Z","timestamp":1762003098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab\u2013bendamustine in follicular lymphoma: a single-center case series study"],"prefix":"10.1007","volume":"151","author":[{"given":"Matteo","family":"D\u2019Addona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Pezzullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Settembre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Guariglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Serio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mettivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gigantiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Signorile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Picone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Cuffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Selleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"6351_CR1","doi-asserted-by":"publisher","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","DOI":"10.1038\/s41375-022-01620-2"},{"issue":"7","key":"6351_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","volume":"70","author":"LS Azevedo","year":"2015","unstructured":"Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TM, Campos SV, Ramos JF, Latif AZ, Litvinov N, Maluf NZ, Caiaffa Filho HH, Pannuti CS, Lopes MH, Santos VA, Linardi Cda C, Yasuda MA, Marques HH (2015) Cytomegalovirus infection in transplant recipients. Clinics (Sao Paulo) 70(7):515\u2013523. https:\/\/doi.org\/10.6061\/clinics\/2015(07)09","journal-title":"Clinics (Sao Paulo)"},{"issue":"8","key":"6351_CR3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.66124","volume":"16","author":"T Chan","year":"2024","unstructured":"Chan T, Champagne JN, Boudreault JS (2024) Efficacy and safety of bendamustine-rituximab as frontline therapy for indolent non-Hodgkin lymphoma: a real-world, single-center, retrospective study. Cureus 16(8):e66124. https:\/\/doi.org\/10.7759\/cureus.66124","journal-title":"Cureus"},{"issue":"1","key":"6351_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4545-7","volume":"19","author":"A Cona","year":"2019","unstructured":"Cona A, Tesoro D, Chiamenti M, Merlini E, Ferrari D, Marti A, Codec\u00e0 C, Ancona G, Tincati C, d\u2019Arminio Monforte A, Marchetti G (2019) Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. BMC Infect Dis 19(1):881. https:\/\/doi.org\/10.1186\/s12879-019-4545-7","journal-title":"BMC Infect Dis"},{"issue":"3","key":"6351_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/01.mco.0000165004.93707.88","volume":"8","author":"C Deans","year":"2005","unstructured":"Deans C, Wigmore SJ (2005) Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8(3):265\u2013269. https:\/\/doi.org\/10.1097\/01.mco.0000165004.93707.88","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"9","key":"6351_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood.2020010028","volume":"3","author":"MA Degli-Esposti","year":"2022","unstructured":"Degli-Esposti MA, Hill GR (2022) Immune control of cytomegalovirus reactivation in stem cell transplantation. Blood 3(9):1277\u20131288. https:\/\/doi.org\/10.1182\/blood.2020010028","journal-title":"Blood"},{"issue":"12","key":"6351_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM (2019) First-line treatment of patients with indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma with Bendamustine plus Rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 37(12):984\u2013991. https:\/\/doi.org\/10.1200\/JCO.18.00605","journal-title":"J Clin Oncol"},{"issue":"9","key":"6351_CR8","first-page":"590","volume":"36","author":"NH Fowler","year":"2011","unstructured":"Fowler NH (2011) Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma. Pharm Ther 36(9):590\u2013598","journal-title":"Pharm Ther"},{"issue":"6","key":"6351_CR9","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-20-0864","volume":"20","author":"T Fujimura","year":"2021","unstructured":"Fujimura T, Yamashita-Kashima Y, Kawasaki N, Yoshiura S, Harada N, Yoshimura Y (2021) Obinutuzumab in combination with chemotherapy enhances direct cell death in CD20-positive obinutuzumab-resistant non-Hodgkin lymphoma cells. Mol Cancer Ther 20(6):1133\u20131141. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0864","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"6351_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/cid\/ciy458","volume":"68","author":"M Fung","year":"2019","unstructured":"Fung M, Jacobsen E, Freedman A, Prestes D, Farmakiotis D, Gu X, Nguyen PL, Koo S (2019) Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis 68(2):247\u2013255. https:\/\/doi.org\/10.1093\/cid\/ciy458","journal-title":"Clin Infect Dis"},{"issue":"8","key":"6351_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70255","volume":"39","author":"C Girmenia","year":"2025","unstructured":"Girmenia C, Lazzarotto T, Martino M, Bonifazi F, Baldanti F, Clerici P, Citterio F, De Carlis L, Barosi G, Grossi PA (2025) Management of cytomegalovirus infection in allogeneic hematopoietic stem cell and in solid organ transplantation: updated recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian societies. Clin Transpl 39(8):e70255. https:\/\/doi.org\/10.1111\/ctr.70255","journal-title":"Clin Transpl"},{"issue":"3","key":"6351_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00277-014-2182-1","volume":"94","author":"T Hasegawa","year":"2015","unstructured":"Hasegawa T, Aisa Y, Shimazaki K, Nakazato T (2015) Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma. Ann Hematol 94(3):515\u2013517. https:\/\/doi.org\/10.1007\/s00277-014-2182-1","journal-title":"Ann Hematol"},{"key":"6351_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04023-y","author":"K Hayashino","year":"2025","unstructured":"Hayashino K, Seike K, Masunari T, Hashida R, Oka S, Fujiwara Y, Terao T, Kitamura W, Kobayashi H, Kamoi C, Kondo T, Fujiwara H, Asada N, Ennishi D, Fujii K, Fujii N, Maeda Y (2025) Cytomegalovirus reactivation in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Int J Hematol. https:\/\/doi.org\/10.1007\/s12185-025-04023-y","journal-title":"Int J Hematol"},{"issue":"9","key":"6351_CR14","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3109\/10428194.2013.856008","volume":"55","author":"F Herting","year":"2014","unstructured":"Herting F, Friess T, Bader S, Muth G, H\u00f6lzlwimmer G, Rieder N, Umana P, Klein C (2014) Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma 55(9):2151\u20135160. https:\/\/doi.org\/10.3109\/10428194.2013.856008","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"6351_CR15","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, D\u00fcrig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36(23):2395\u20132404. https:\/\/doi.org\/10.1200\/JCO.2017.76.8960","journal-title":"J Clin Oncol"},{"issue":"6","key":"6351_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3109\/10428194.2012.739285","volume":"54","author":"T Hosoda","year":"2013","unstructured":"Hosoda T, Yokoyama A, Yoneda M, Yamamoto R, Ohashi K, Kagoo T, Ueno H, Boku S, Yano T (2013) Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma 54(6):1327\u20131328. https:\/\/doi.org\/10.3109\/10428194.2012.739285","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"6351_CR17","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.3109\/10428194.2015.1126589","volume":"57","author":"N Isono","year":"2016","unstructured":"Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J (2016) Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leuk Lymphoma 57(9):2204\u20132207. https:\/\/doi.org\/10.3109\/10428194.2015.1126589","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6351_CR18","doi-asserted-by":"publisher","first-page":"923","DOI":"10.21873\/invivo.13520","volume":"38","author":"K Ito","year":"2024","unstructured":"Ito K, Koseki T, Morisaku M, Yamada S, Hayakawa N (2024) Cytomegalovirus occurrence and time-to-onset analysis under bendamustine with anti-CD20 antibodies using the JADER database. In Vivo 38(2):923\u2013927. https:\/\/doi.org\/10.21873\/invivo.13520","journal-title":"In Vivo"},{"issue":"12","key":"6351_CR19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen E (2022) Follicular lymphoma: 2023 update on diagnosis and management. Am J Hematol 97(12):1638\u20131651. https:\/\/doi.org\/10.1002\/ajh.26737","journal-title":"Am J Hematol"},{"issue":"4","key":"6351_CR20","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/cid\/ciad708","volume":"10","author":"E Kampouri","year":"2024","unstructured":"Kampouri E, Ibrahimi SS, Xie H, Wong ER, Hecht JB, Sekhon MK, Vo A, Stevens-Ayers TL, Green DJ, Gauthier J, Maloney DG, Perez A, Jerome KR, Leisenring WM, Boeckh MJ, Hill JA (2024) Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy. Clin Infect Dis 10(4):1022\u20131032. https:\/\/doi.org\/10.1093\/cid\/ciad708","journal-title":"Clin Infect Dis"},{"issue":"9","key":"6351_CR21","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1007\/s10072-025-08329-x","volume":"46","author":"B Karaman","year":"2025","unstructured":"Karaman B, Din\u00e7er G, Tun\u00e7el R, Ekmekci O, Y\u00fcceyar N (2025) Secondary hypogammaglobulinemia and lymphocytopenia in patients with inflammatory neurological diseases on anti-CD20 therapy: risk of infection and infection-related mortality. Neurol Sci 46(9):4569\u20134574. https:\/\/doi.org\/10.1007\/s10072-025-08329-x","journal-title":"Neurol Sci"},{"issue":"2","key":"6351_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","volume":"133","author":"S Kusumoto","year":"2019","unstructured":"Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K (2019) Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 133(2):137\u2013146. https:\/\/doi.org\/10.1182\/blood-2018-04-848044","journal-title":"Blood"},{"issue":"6","key":"6351_CR23","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8325","volume":"47","author":"H Lalic","year":"2022","unstructured":"Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A (2022) Bendamustine: a review of pharmacology, clinical use and immunological effects (review). Oncol Rep 47(6):114. https:\/\/doi.org\/10.3892\/or.2022.8325","journal-title":"Oncol Rep"},{"issue":"1","key":"6351_CR24","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12885-022-09772-1","volume":"22","author":"S Lara","year":"2022","unstructured":"Lara S, Heilig J, Virtanen A, Kleinau S (2022) Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma. BMC Cancer 22(1):678. https:\/\/doi.org\/10.1186\/s12885-022-09772-1","journal-title":"BMC Cancer"},{"issue":"4","key":"6351_CR25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00277-011-1307-z","volume":"91","author":"SH Lim","year":"2012","unstructured":"Lim SH, Pathapati S, Langevin J, Hoot A (2012) Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 91(4):643\u2013644. https:\/\/doi.org\/10.1007\/s00277-011-1307-z","journal-title":"Ann Hematol"},{"issue":"8","key":"6351_CR26","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","volume":"25","author":"P Ljungman","year":"2025","unstructured":"Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, Sadowska-Klasa A, Navarro D, Styczynski J, de la Camara R (2025) Recommendations from the 10th European conference on infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis 25(8):e451\u2013e462. https:\/\/doi.org\/10.1016\/S1473-3099(25)00069-6","journal-title":"Lancet Infect Dis"},{"key":"6351_CR27","doi-asserted-by":"publisher","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN; 2017 European Conference on Infections in Leukaemia group (2019) Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19(8):e260\u2013e272. https:\/\/doi.org\/10.1016\/S1473-3099(19)30107-0","DOI":"10.1016\/S1473-3099(19)30107-0"},{"issue":"14","key":"6351_CR28","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"5","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trn\u011bn\u00fd M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 5(14):1331\u20131344. https:\/\/doi.org\/10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"key":"6351_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5762525","volume":"2017","author":"L Modvig","year":"2017","unstructured":"Modvig L, Boyle C, Randall K, Borg A (2017) Severe cytomegalovirus reactivation in patient with low-grade non-Hodgkin\u2019s lymphoma after standard chemotherapy. Case Rep Hematol 2017:5762525. https:\/\/doi.org\/10.1155\/2017\/5762525","journal-title":"Case Rep Hematol"},{"issue":"10","key":"6351_CR30","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.cmi.2022.05.034","volume":"28","author":"DSY Ong","year":"2022","unstructured":"Ong DSY, Chong GM, Chemaly RF, Cremer OL (2022) Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. Clin Microbiol Infect 28(10):1335\u20131344. https:\/\/doi.org\/10.1016\/j.cmi.2022.05.034","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"6351_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s43188-024-00233-4","volume":"40","author":"M Park","year":"2024","unstructured":"Park M, Kim JW (2024) Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer. Toxicol Res 40(3):335\u2013348. https:\/\/doi.org\/10.1007\/s43188-024-00233-4","journal-title":"Toxicol Res"},{"issue":"6","key":"6351_CR32","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M (2020) The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica 105(6):1494\u20131506. https:\/\/doi.org\/10.3324\/haematol.2019.243543","journal-title":"Haematologica"},{"issue":"1","key":"6351_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1515\/med-2021-0274","volume":"16","author":"L Pezzullo","year":"2021","unstructured":"Pezzullo L, Giudice V, Serio B, Fontana R, Guariglia R, Martorelli MC, Ferrara I, Mettivier L, Bruno A, Bianco R, Vaccaro E, Pagliano P, Montuori N, Filippelli A, Selleri C (2021) Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens. Open Med 16(1):672\u2013682. https:\/\/doi.org\/10.1515\/med-2021-0274","journal-title":"Open Med"},{"issue":"1","key":"6351_CR34","doi-asserted-by":"publisher","first-page":"e2024065","DOI":"10.4084\/MJHID.2024.065","volume":"16","author":"JL Pi\u00f1ana","year":"2024","unstructured":"Pi\u00f1ana JL, Gim\u00e9nez E, V\u00e1zquez L, Marcos M\u00c1, Guerreiro M, Duarte R, P\u00e9rez A, de Miguel C, Espigado I, Gonz\u00e1lez-Vicent M, Suarez-Lled\u00f3 M, Garc\u00eda-Cadenas I, Martino R, Cedillo A, Rovira M, de la C\u00e1mara R, Navarro D, Solano C (2024) Update on cytomegalovirus infection management in allogeneic hematopoietic stem cell transplant recipients A consensus document of the spanish group for hematopoietic transplantation and cell therapy (GETH-TC). Mediterr J Hematol Infect Dis. 16(1):e2024065. https:\/\/doi.org\/10.4084\/MJHID.2024.065","journal-title":"Mediterr J Hematol Infect Dis."},{"issue":"1","key":"6351_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3324\/haematol.2021.278717","volume":"107","author":"D Qualls","year":"2022","unstructured":"Qualls D, Salles G (2022) Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica 107(1):19\u201334. https:\/\/doi.org\/10.3324\/haematol.2021.278717","journal-title":"Haematologica"},{"issue":"3","key":"6351_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3960\/jslrt.23015","volume":"63","author":"M Saburi","year":"2023","unstructured":"Saburi M, Okuhiro K, Yoshida N, Haruyama T, Moroga Y, Yanai Y, Itani K, Takano K, Honda S, Ono K, Iwanaga M, Sasaki H, Abe M, Kohno K, Nakayama T, Ohtsuka E, Ogata M (2023) Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world study. J Clin Exp Hematop 63(3):197\u2013200. https:\/\/doi.org\/10.3960\/jslrt.23015","journal-title":"J Clin Exp Hematop"},{"issue":"10","key":"6351_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.86","volume":"5","author":"H Saito","year":"2015","unstructured":"Saito H, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Taniguchi H, Tobinai K (2015) Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J 5(10):e362. https:\/\/doi.org\/10.1038\/bcj.2015.86","journal-title":"Blood Cancer J"},{"issue":"1","key":"6351_CR38","first-page":"102","volume":"29","author":"B Serio","year":"2021","unstructured":"Serio B, Giudice V, Guariglia R, Fontana R, Pezzullo L, Martorelli MC, Ferrara I, Mettivier L, D\u2019Addona M, Vaccaro E, Langella M, Selleri C (2021) Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study. Infez Med 29(1):102\u2013113","journal-title":"Infez Med"},{"issue":"9","key":"6351_CR39","first-page":"92","volume":"65","author":"SVK Singhania","year":"2017","unstructured":"Singhania SVK, Parikh P, Goyle S (2017) CMV pneumonitis following bendamustine containing chemotherapy. J Assoc Phys India 65(9):92\u201393","journal-title":"J Assoc Phys India"},{"issue":"2","key":"6351_CR40","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","volume":"34","author":"K Tobinai","year":"2017","unstructured":"Tobinai K, Klein C, Oya N, Fingerle-Rowson G (2017) A review of Obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther 34(2):324\u2013356. https:\/\/doi.org\/10.1007\/s12325-016-0451-1","journal-title":"Adv Ther"},{"issue":"7","key":"6351_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919","volume":"7","author":"W Townsend","year":"2023","unstructured":"Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R (2023) Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study. Hemasphere 7(7):e919. https:\/\/doi.org\/10.1097\/HS9.0000000000000919","journal-title":"Hemasphere"},{"issue":"31","key":"6351_CR42","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trn\u011bn\u00fd M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH (2017) Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 35(31):3529\u20133537. https:\/\/doi.org\/10.1200\/JCO.2017.73.3402","journal-title":"J Clin Oncol"},{"issue":"2","key":"6351_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47(2):115\u2013123. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.011","journal-title":"Semin Hematol"},{"issue":"43","key":"6351_CR44","doi-asserted-by":"publisher","first-page":"73654","DOI":"10.18632\/oncotarget.18359","volume":"8","author":"L Xia","year":"2017","unstructured":"Xia L, Tang A, Meng W, Freed DC, He L, Wang D, Li F, Li L, Xiong W, Gui X, Schultz RD, Chen H, He X, Swoyer R, Ha S, Liu Y, Morris CD, Zhou Y, Wang IM, Zhao Q, Luo W, Xia N, Espeseth AS, Hazuda DJ, Rupp RE, Barrett AD, Zhang N, Zhu J, Fu TM, An Z (2017) Active evolution of memory B-cells specific to viral gH\/gL\/pUL128\/130\/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection. Oncotarget 8(43):73654\u201373669. https:\/\/doi.org\/10.18632\/oncotarget.18359","journal-title":"Oncotarget"},{"issue":"7","key":"6351_CR45","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00277-017-3005-y","volume":"96","author":"S Yamasaki","year":"2017","unstructured":"Yamasaki S, Kohno K, Kadowaki M, Takase K, Iwasaki H (2017) Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine. Ann Hematol 96(7):1215\u20131217. https:\/\/doi.org\/10.1007\/s00277-017-3005-y","journal-title":"Ann Hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06351-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T19:38:54Z","timestamp":1765654734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06351-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6351"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06351-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Protocol approved by local ethic committee (Ethics Committee \u201cCampania Sud\u201d, Brusciano, Naples, Italy; prot.\/SCCE n. 24988).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients received informed consent obtained in accordance with the Declaration of Helsinki (World Medical Association 2013) and protocols approved by local ethic committee (Ethics Committee \u201cCampania Sud\u201d, Brusciano, Naples, Italy; prot.\/SCCE n. 24988).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"312"}}